EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its investigational treatment DURAVYU (vorolanib intravitreal insert) failed to meet the primary endpoint in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA